However, an alternate approach is to target this pathway with mTOR kinase inhibitors that potently inhibit mTORC1 as well as mTORC2, thus inhibiting Akt S473 phosphorylation, and thereby preventing or attenuating the feedback loop activation of Akt and potentially treating PI3K/mTOR dependent cancers more effectively [23]. Here, AKT1 is linked to cancer.